Get the Stockscreener App
0.3038
1.94%
-0.0062
Azitra Inc stock is traded at $0.3038, with a volume of 466.65K.
It is down -1.94% in the last 24 hours and up +14.72% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.31
Open:
$0.3016
24h Volume:
466.65K
Relative Volume:
0.08
Market Cap:
$4.45M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0135
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
+2.32%
1M Performance:
+14.72%
6M Performance:
-36.77%
1Y Performance:
+34.28%
1-Day Range:
$0.291
$0.307
1-Week Range:
$0.282
$0.3398
52-Week Range:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.3035 | 4.45M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.70 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.18 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.39 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.38 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.48 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Azitra Inc Stock (AZTR) Latest News
Stock Of Azitra Inc (AMEX: AZTR) Jumped By 6.67 Percent Over The Past Month, Is There Room For Upside? - Marketing Sentinel
Azitra Inc (AZTR)’s Day in Review: Closing at 0.30, Down by -6.51 - DWinneX
Azitra Inc (AZTR) Stock: Navigating Drops and Gains - investchronicle.com
Azitra Inc [AZTR] Investment Appeal on the Rise - knoxdaily.com
Azitra Inc (AMEX:AZTR) stock: You might be surprised - uspostnews.com
Stocks of Azitra Inc (AZTR) are poised to climb above their peers - Sete News
Azitra (AZTR) Secures Funding Through $20 Million Share Purchase Agreement - GuruFocus
What to expect from Azitra Inc’s (AZTR) current quarter earnings? - uspostnews.com
AZTR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Branford-based biopharma Azitra Inc. gains $20M in partnership deal with Alumni Capital - Hartford Business Journal
Azitra (AZTR) to Highlight Precision Dermatology Advances at Bru - GuruFocus
Market Momentum: Azitra Inc (AZTR) Registers a 3.73 Increase, Closing at 0.31 - DWinneX
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025 - Morningstar
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Revolutionary Fast-Track Therapy Targets Major Cancer Treatment Side Effect: Phase 1/2 Trial Launches at ASCO 2025 - Stock Titan
Azitra enters share purchase agreement with Alumni Capital for up to $20M - MSN
Azitra secures funding deal for dermatology treatments By Investing.com - Investing.com India
Azitra secures funding deal for dermatology treatments - Investing.com
$20M Strategic Investment Accelerates Azitra's Breakthrough Treatments for 150,000 Rare Disease Patients - Stock Titan
Azitra (NYSEAMERICAN:AZTR) Trading Up 3.9% – Here’s Why - Defense World
Azitra Announces Proposed Public Offering of Common Stock (PR Newswire) - Aktiellt
Azitra, Inc. (NYSEAMERICAN:AZTR) Shares Acquired by Virtu Financial LLC - Defense World
Teacher Retirement System of Texas Makes New $236,000 Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
Azitra (AZTR) Expected to Announce Quarterly Earnings on Friday - Defense World
Azitra to Present at Microbiome Times Partnering Forum – Company Announcement - Financial Times
Azitra to Present at Microbiome Times Partnering Forum - PR Newswire
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
AZTR: Netherton Topline Expected by Year-End - MSN
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Up 144.1% in February - Defense World
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates - Citizentribune
Azitra, Inc. Announces FY 2024 Financial Results and Business Updates - Defense World
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating - Investing.com
Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating By Investing.com - Investing.com South Africa
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle - HPBL
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.30%
Cap:
|
Volume (24h):